[Long-acting neuroleptics. IV. Preliminary study of clopimozide (R 29764)].
Clopimozide is, in our opinion, a noteworthy neuroleptic drug. Its action is mainly ataraxic but also antidelusional, long-acting and accompanied with minimal side-effects. It is therefore particularly indicated in the maintenance therapy of psychotics, at a weekly dosage of 7.5 to 25 mg. The present conclusions are preliminary because of the limited number of patients (10) but also because of the rigidity of the trial protocol suggested to us.
D000275:Adjustment Disorders / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D001562:Benzimidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use*
D001562:Benzimidazoles; D010880:Piperidines; D014149:Tranquilizing Agents
Neuroleptiques à longue durée d'action. IV. Etude préliminaire du clopimozide (R 29764)